Evidence map›Paper›PMID 31364974›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2019

Quality and cost assessment of Canadian Urological Association microscopic hematuria guidelines in clinical practice: Turning urine into gold.

Mark A Assmus, David B Beyer, Joan Hanks, Mathew Estey, Keith F Rourke, Trevor Schuler, Tim A Wollin

Open access · diamondAbstract read
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Inappropriate use of clinical practices in Canada: a systematic review.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022
    Pooled it
  2. Genitourinary malignancy among patients presenting with microscopic hematuria in Northwestern Ontario.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
    Article
  3. Taking a more critical look at the use of costly and invasive testing.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2019
    Article
  4. Optimizing management of patients with microhematuria: Gold down the drain?Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mark A AssmusDepartment of Surgery, Division of Urology, Edmonton, AB, Canada.
David B BeyerDepartment of Laboratory Medicine and Pathology, Edmonton, AB, Canada.
Joan HanksDynaLIFE Medical Laboratories, Edmonton, AB, Canada.
Mathew EsteyDepartment of Laboratory Medicine and Pathology, Edmonton, AB, Canada.
Keith F RourkeDepartment of Surgery, Division of Urology, Edmonton, AB, Canada.
Trevor SchulerDepartment of Surgery, Division of Urology, Edmonton, AB, Canada.
Tim A WollinDepartment of Surgery, Division of Urology, Edmonton, AB, Canada.
University of Alberta Hospital · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAsymptomatic microscopic hematuria (AMH) is defined in the Canadian Urological Association (CUA) guideline as >2 red blood cells (RBCs) per high-powered field (HPF). Our objective was to evaluate guideline adherence for AMH at our center. Secondarily, we aimed to identify areas of the guideline that can be optimized.

methodsWe retrospectively reviewed 875 consecutive adults referred to two urologists for hematuria between June 2010 and June 2016. Patient characteristics, risk factors, and outcomes were added to an encrypted Research Electronic Data Capture (REDCap) database. Evaluation of microscopic hematuria reporting was performed by analyzing 681 urine samples reported as 1-5 RBC/HPF. Healthcare costs were obtained from Alberta Health Services (AHS), Data Integration and Management Repository (DIMR), and Alberta Society of Radiologists (ASR).

resultsOf the 875 patients referred with hematuria, 400 had AMH. Overall, 96.5% completed evaluation consistent with the CUA guideline. The incidence of pathology requiring surgical intervention was 21/400 (5%) with a 0.8% rate (3/400) of urothelial cell carcinoma (UCC) (non-invasive, low-grade). No malignancy was found in non-smokers with normal cytology, normal imaging and <50 RBC/HPF; 44% had AMH in the 1-5 RBCs/HPF range. Only 41% (279/681) of urine samples categorized as 1-5 RBCs/ HPF had guideline-defined microscopic hematuria. By changing local microscopic hematuria reporting to differentiate 1-2 and 3-5 RBCs/HPF, we estimate $745 000 in annual savings.

conclusionsAt our center, CUA AMH guideline adherence is high. We did not find malignancy in non-smokers with normal cytology, imaging and <50 RBC/HPF. We identified and changed regional microscopic hematuria reporting to fit the CUA definition, eliminating unnecessary investigations and healthcare costs.

Identifiers

PMID31364974
PMCPMC6892690
OpenAlexW2914624304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.